Ceftriaxone: Clinical Overview
Ceftriaxone is a third-generation cephalosporin administered intravenously or intramuscularly at doses of 1-2 grams once or twice daily for most adult infections, with specific dosing adjustments based on infection severity, renal function, and pathogen susceptibility.
Indications
Ceftriaxone is indicated for serious bacterial infections including:
- Meningitis: Empiric treatment for bacterial meningitis in adults <60 years at 2 g IV every 12 hours; for adults ≥60 years, add amoxicillin 2 g every 4 hours to cover Listeria 1
- Pneumococcal meningitis: Continue 2 g IV every 12 hours for 10-14 days depending on clinical response 1
- Meningococcal meningitis: 2 g IV every 12 hours for 5 days if recovered 1
- Community-acquired pneumonia: 1-2 g daily combined with a macrolide or as monotherapy with a respiratory fluoroquinolone 2
- Bacteremia/septicemia: 1-2 g daily, though recent data suggest 2 g may not improve outcomes over 1 g for routine cases 3
- Disseminated gonococcal infection: 1 g IM or IV every 24 hours 4
- Uncomplicated gonorrhea: Single 250 mg IM dose 4
- Skin/soft tissue infections: 1-2 g daily 5
- Urinary tract infections: 1-2 g daily 5
Dosing Regimens
Standard Adult Dosing
General infections: 1-2 g IV/IM once daily or in equally divided doses twice daily, not exceeding 4 g/day 5
Severe infections/meningitis: 2 g IV every 12 hours 1
Surgical prophylaxis: Single 1 g IV dose 0.5-2 hours before surgery 5
Renal Function-Based Dosing
Critical insight: No dosage adjustment is necessary for renal or hepatic impairment up to 2 g/day 5. However, recent pharmacokinetic data suggest more nuanced dosing:
- eGFR ≤60 mL/min/1.73 m²: 1 g every 24 hours 6
- eGFR >60 mL/min/1.73 m²: 1 g every 12 hours 6
- Augmented renal clearance (CrCl >130 mL/min): Consider 4 g/day as continuous infusion for pathogens with MIC ≥0.5 mg/L 7
Special Populations
Neonates:
- Contraindicated in premature neonates and those ≤28 days requiring calcium-containing IV solutions 5
- Hyperbilirubinemic neonates should not receive ceftriaxone 5
- If used, administer IV over 60 minutes to reduce bilirubin encephalopathy risk 5
Pediatric patients:
- Meningitis: Initial dose 100 mg/kg (max 4 g), then 100 mg/kg/day for 7-14 days 5
- Serious infections: 50-75 mg/kg/day, max 2 g/day 5
- Acute otitis media: Single 50 mg/kg IM dose (max 1 g) 5
Elderly: No modification needed up to 2 g/day if no severe renal/hepatic impairment 5
Administration
IV infusion: Administer over 30 minutes in adults; 60 minutes in neonates 5
Concentration: 10-40 mg/mL recommended 5
IM injection: Inject into large muscle mass; aspirate to avoid vascular injection 5
Contraindications
Absolute contraindications:
- Hypersensitivity to ceftriaxone or other cephalosporins 5
- Premature neonates 5
- Neonates ≤28 days requiring calcium-containing IV solutions 5
- Hyperbilirubinemic neonates, especially premature infants 5
Critical warning: Never mix ceftriaxone with calcium-containing solutions (Ringer's, Hartmann's) due to precipitation risk 5. In non-neonates, sequential administration is acceptable only if lines are thoroughly flushed between infusions 5.
Monitoring Parameters
Hypoalbuminemia consideration: Albumin ≤20 g/L decreases probability of target attainment by up to 20%, particularly with intermittent dosing 7. Consider higher doses or continuous infusion in hypoalbuminemic patients.
Pharmacodynamic target: Free trough concentration/MIC ratio ≥1 for optimal efficacy 7
Target attainment:
- Standard 2 g every 24 hours achieves >90% PTA for MIC ≤2 mg/L in non-ICU patients 8
- For MIC 4 mg/L with eGFR 122 mL/min/1.73 m², PTA drops to 56.9% 8
- For MIC 8 mg/L, inadequate PTA regardless of renal function 8
Adverse events to monitor:
- Diarrhea (more common with higher doses) 9
- Thrombocytopenia/leukopenia 9
- Eosinophilia 9
- Biliary tract complications (slightly higher with 2 g/day) 10
- Clostridioides difficile infection risk 10
Clinical Pearls
Resistance development: 4 of 31 aerobic gram-negative isolates developed resistance during therapy in one study 9, emphasizing the need for susceptibility monitoring.
Severe pneumonia: For patients requiring mechanical ventilation, 2 g/day was associated with lower 30-day mortality (17.2% vs 20.4%) compared to 1 g/day 10. Consider higher dosing in critically ill pneumonia patients.
Routine bacteremia: No significant difference in clinical failure between 1 g and 2 g daily dosing for uncomplicated bacteremia 3. Use 1 g daily unless severe infection or resistant pathogen suspected.
Duration: Continue for at least 2 days after signs/symptoms resolve; typical duration 4-14 days depending on infection type 5. For Streptococcus pyogenes, continue at least 10 days 5.
Incompatibilities: Do not mix with vancomycin, aminoglycosides, amsacrine, or fluconazole 5